[Changes of serum interleukin 2 and soluble interleukin 2 receptor and their clinical significance in multiple myeloma].
Serum interleukin 2 (IL-2) and soluble interleukin 2 receptor (sIL-2R) were serially determined in 44 patients with multiple myeloma (MM) by radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA). Serum IL-2 and sIL-2R levels of 24 cases in stage I and II were not different from those in normal individuals. However, serum IL-2 level of 20 cases in stage III was significantly lower than that of normal individuals and of MM patients in stage I and II, while the serum sIL-2R level was significantly increased. The changes in serum IL-2 and sIL-2R level could reflect the severity of the disease.
Wang
Z
Z
Affiliated Hospital, Weifang Medical College.
Li
D
D
Yang
J
J
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood*; D015375:Receptors, Interleukin-2 / Q000097:blood*
D007376:Interleukin-2; D015375:Receptors, Interleukin-2